Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | EVICITON: ICT01 plus pembro induces broad antitumor response in NSCLC, bladder cancer and melanoma

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of The Phase I/II EVICITON (NCT04243499) trial evaluating the combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab in patients with CPI-failure melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. ICT01 may enhance the recruitment of immune cells to the tumor site, providing the rationale to combine with immune checkpoint blockade. The Phase I dose escalation treatment with ICT01 plus pembrolizumab induced disease control in 42% of melanoma, 22% of non-small-cell lung carcinoma and 22% of bladder cancer patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.